In therapeutic cancer vaccines, vaccine antigens must be efficiently delivered to the antigen-
presenting cells (dendritic cells and macrophages) located in the lymphoid organs (lymph …

Sphingolipids are an extensive class of lipids with different functions in the cell, ranging from
proliferation to cell death. Sphingolipids are modified in multiple cancers and are …

Therapeutic proteins are well-tolerated bioactive compounds used in different therapies, due
to its high specificity and biopotency. Nevertheless, they may also present some …

Dendritic cells (DCs) are paramount in initiating and guiding immunity towards a state of
activation or tolerance. This bidirectional capacity of DCs sets them at the center stage for …

Langerhans cells (LCs) constitute a cellular immune network across the epidermis. Because
they are located at the skin barrier, they are considered immune sentinels of the skin. These …

Successful anti-cancer vaccines aim to prime and reinvigorate cytotoxic T cells and should
therefore comprise a potent antigen and adjuvant. Antigen targeting to splenic CD169+ …

Cancer immunity is dependent on dynamic interactions between T cells and dendritic cells
(DCs). Polymer-based nanoparticles target DC receptors to improve anticancer immune …

Dendritic cells (DCs) control adaptive immunity and are therefore attractive for in vivo
targeting to either induce immune activation or tolerance, depending on disease …

Vaccination strategies against mycobacteria, focusing mostly on classical T‐and B‐cells,
have shown limited success, encouraging the addition of alternative targets. Classically …

Specific neoantigens are promising candidates for personalized cancer vaccines and
immunotherapies, whereas the low immunogenicity and physicochemical variability are the …